MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver.

MHRA-100472-PIP01-22

Scope of the Application

Active Substance(s)

Tarlatamab

Condition(s)

Treatment of small cell lung cancer (SCLC), Treatment of prostate malignant neoplasms.

Pharmaceutical Form(s)

All pharmaceutical forms.

Route(s) of Administration

All routes of administration.

Name / Corporate name of the PIP applicant

Amgen Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Amgen Limited submitted to the licensing authority on 18/03/2022 10:41 GMT an application for a Waiver

The procedure started on 20/10/2022 08:55 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100472-PIP01-22

Of 18/11/2022 08:37 GMT

On the adopted decision for Tarlatamab (MHRA-100472-PIP01-22) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s).

This decision applies to a Waiver for Tarlatamab, All pharmaceutical forms. , All routes of administration. .

This decision is addressed to Amgen Limited, 216 Cambridge Science Park, Cambridge, UNITED KINGDOM, CB4 0WA

ANNEX I

1. Waiver

1.1 Condition:

Treatment of small cell lung cancer (SCLC). Treatment of prostate malignant neoplasms.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable.

2.2 Indication(s) targeted by the PIP:

Not applicable.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable.

2.4 Pharmaceutical Form(s):

Not applicable.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	